New hope for advanced breast cancer: early trial of oral drug LY3484356 begins
NCT ID NCT05509790
First seen Apr 18, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This early-phase study tests an oral drug called LY3484356 in 17 Chinese patients with advanced ER+/HER2- breast cancer. The main goals are to see how the drug moves through the body and to check its safety. Researchers will also look for signs that the drug can shrink tumors or control the disease. Participation can last up to 28 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 201315, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
The Third Hospital of Nanchang
Nanchang, Jiangxi, 330025, China
-
Wannan Medical College Yijishan Hospital
Wuhu, Anhui, 241001, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY3484356 (an oral drug)
What this could lead to
If successful, this could lead to a new oral treatment option for Chinese patients with advanced ER+/HER2- breast cancer.
What could go wrong
This is a very early phase 1 study with only 17 participants, so results may not apply broadly. The drug may not prove effective or could have unexpected side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.